比较甲基强的松龙与氢化可的松治疗毛细支气管炎的疗效。

选取2008年1月至2009年7月在本院儿科确诊为毛细支气管炎的患儿63例为研究对象，将其随机分为，治疗组(n＝31)在常规治疗基础上，静脉输注甲基强的松龙(1～2) mg/(kg·d)×5 d；对照组(n＝32)在常规治疗的基础上，静脉输注氢化可的松(5～10)mg/(kg·d)×5 d，两组均同时静脉输注氨茶碱3 mg/(kg·d)，进行平喘治疗，症状好转后改为口服给药方式(本研究遵循的程序符合本院人体试验委员会制定的伦理学标准，得到该委员会批准，分组征得受试对象监护人的知情同意，并与其签署临床研究知情同意书)。两组患儿的性别、年龄、毛细支气管炎症状与体征比较，差异无显著意义(P>0.05)。

治疗组总有效率明显高于对照组(25/31，80.65% vs. 17/32，53.13%)，差异有显著意义(P<0.05)；治疗组患儿住院时间明显短于对照组[(7.03±1.22)d vs.(9.75±1.41)d]，差异有显著意义(P<0.05)。

甲基强的松龙治疗毛细支气管炎具有较好疗效，且安全。

To compare therapeutic effects between methylprednisolone and hydrocortisone on treatment of bronchiolitis.

From January 2008 to July 2009, 63 children with bronchiolitis were randomly divided into two groups, 31 cases were treated with methylprednisolone (1-2 )mg/(kg·d)×5-day+ aminofilina (3 mg/kg) intravenous infusion under conventional therapy (treatment group), another 32 cases were treated with hydrocortisone(5-10) mg/(kg·d) ×5-day+ aminofilina (3 mg/kg) intravenous infusion under conventional therapy (control group). Both groups were changed to oral administration when symptoms improved. Informed consent was obtained from all participants. Comparison between gender, ages, symptoms, and physical signs had no significant.

The total effective rate of treatment group was significantly higher than that of control group(25/31, 80.65% vs. 17/32, 53.13%, P<0.05), and the hospitalize time of treatment group was significantly shorter than that of control group [(7.03±1.22)d vs.(9.75±1.41)d, P<0.05].

Methyprednisolone is effective and safe in treatment of bronchiolitis.